APA (7th ed.) Citation

M, P., A, D. G., F, R., F, A., C, P., E, M., . . . DI, B. (2026). Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study. Epilepsia open, 11(2), 466. https://doi.org/10.1002/epi4.70213

Chicago Style (17th ed.) Citation

M, Perulli, et al. "Highly Purified Cannabidiol (CBD) in CDKL5 Deficiency Disorder (CDD): Open-label Prospective Study." Epilepsia Open 11, no. 2 (2026): 466. https://doi.org/10.1002/epi4.70213.

MLA (9th ed.) Citation

M, Perulli, et al. "Highly Purified Cannabidiol (CBD) in CDKL5 Deficiency Disorder (CDD): Open-label Prospective Study." Epilepsia Open, vol. 11, no. 2, 2026, p. 466, https://doi.org/10.1002/epi4.70213.